France adopts Gardasil as human papillomavirus vaccine
Girls aged 14 or above in France should be vaccinated with US drug major Merck & Co's Gardasil (human papillomavirus vaccine), according to an announcement by the country's senior health council (HAS). The vaccine is marketed in France by Sanofi Pasteur MSD, a joint venture between the US firm and local drug giant Sanofi-Aventis. Local media reports suggested that the HAS considered Gardasil to be preferable to UK-headquartered GlaxoSmithKline's similar product, Cervarix. The selected vaccine protects against four strains of HPV versus two for GSK's version.
A catch-up program is also recommended for women aged 15 to 23, either before or within the first year of sexual contact. The announcement is in line with several European Union members states (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze